Recent submissions
Now showing items 2861-2880 of 4716
-
Genetic characterisation of radiation-induced breast cancer in survivors of Hodgkin's lymphoma
(Institute of Cancer Research (University Of London), 2019-08-31)Hodgkin's lymphoma (HL) accounts for less than one percent of new cancer cases every year in the UK. Although historically HL patients had a poor prognosis, decades of treatments for this hematopoietic neoplasm have led ... -
Simulation of a radiobiology facility for the Centre for the Clinical Application of Particles.
(ELSEVIER SCI LTD, 2019-09-01)The Centre for the Clinical Application of Particles' Laser-hybrid Accelerator for Radiobiological Applications (LhARA) facility is being studied and requires simulation of novel accelerator components (such as the Gabor ... -
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
(AMER ASSOC CLINICAL CHEMISTRY, 2019-11-01)BACKGROUND: Circulating tumor DNA (ctDNA) assays are increasingly used for clinical decision-making, but it is unknown how well different assays agree. We aimed to assess the agreement in ctDNA mutation calling between ... -
Radiotherapy Trial Set up in the UK: Identifying inefficiencies and potential solutions
(Elsevier, 2019-11-01) -
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
(ELSEVIER IRELAND LTD, 2020-01-01)BACKGROUND AND PURPOSE: Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced (IGRT-R) ... -
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
(BMC, 2019-12-31)BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major clinical problem. In this study, we sought to investigate the impact of aromatase inhibitor (AI) therapy on gene expression ... -
Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.
(AMER SOC CLINICAL ONCOLOGY, 2018-01-01)PURPOSE: To describe a snapshot of international genetic testing practices, specifically regarding the use of multigene panels, for hereditary breast/ovarian cancers. We conducted a survey through the Evidence-Based Network ... -
Adaptive trial designs: what is the continual reassessment method?
(BMJ PUBLISHING GROUP, 2021-06-01) -
Supervised Machine-Learning Enables Segmentation and Evaluation of Heterogeneous Post-treatment Changes in Multi-Parametric MRI of Soft-Tissue Sarcoma.
(FRONTIERS MEDIA SA, 2019-10-10)Background: Multi-parametric MRI provides non-invasive methods for response assessment of soft-tissue sarcoma (STS) from non-surgical treatments. However, evaluation of MRI parameters over the whole tumor volume may not ... -
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
(AMER ASSOC CANCER RESEARCH, 2020-02-01)PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1, and OncoMasTR Risk Score (OMclin2) prognostic scores for prediction of distant recurrence (DR) in estrogen receptor (ER)-positive/HER2-negative ... -
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
(TAYLOR & FRANCIS LTD, 2019-10-30)Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ... -
Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk.
(BMC, 2019-04-30)BACKGROUND: It is well established that estrogens and other hormonal factors influence breast cancer susceptibility. We hypothesized that a woman's total lifetime estrogen exposure accumulates changes in DNA methylation, ... -
Two truncating variants in FANCC and breast cancer risk.
(NATURE PORTFOLIO, 2019-08-29)Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported to date. In some FA genes, monoallelic mutations have been found to be associated with breast cancer risk, while the risk ... -
De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder.
(CELL PRESS, 2019-04-04)The Mediator is an evolutionarily conserved, multi-subunit complex that regulates multiple steps of transcription. Mediator activity is regulated by the reversible association of a four-subunit module comprising CDK8 or ... -
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
(NATURE PUBLISHING GROUP, 2020-01-01)The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become ... -
Adaptive trial designs: what are multiarm, multistage trials?
(BMJ PUBLISHING GROUP, 2020-12-01) -
Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis.
(OXFORD UNIV PRESS INC, 2019-10-30)BACKGROUND: The etiological basis of glioma is poorly understood. We have used genetic markers in a Mendelian randomization (MR) framework to examine if lifestyle, cardiometabolic, and inflammatory factors influence the ... -
ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma.
(AMER ASSOC CANCER RESEARCH, 2019-10-15)Tumor cells proliferate rapidly and thus are frequently subjected to replication stress and the risk of incomplete duplication of the genome. Fragile sites are replicated late, making them more vulnerable to damage when ... -
The Diversification of Cell Death and Immunity: Memento Mori.
(CELL PRESS, 2019-10-01)Why do cells have so many ways to die? Why does "cellular suicide" exist at all? In the war against pathogens and rogue cells, organisms developed cellular suicide as a last resort. Fighting an evolutionary arms race, cell ...